ADORA2A and neoplasm: The first clinical trial, using A2AR antagonist in combination with anti-PDL1 in patients with refractory renal cell cancer, resulted in a clinical benefit associated with an augmented recruitment of CD8+ T cells into the tumor and a generation of novel T cell clones in peripheral blood (Fong et al., 2020).